copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
label - Food and Drug Administration Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR), which is activated by aldosterone and cortisol and regulates gene transcription Finerenone blocks MR mediated sodium reabsorption and MR overactivation in both epithelial (e g , kidney) and nonepithelial (e g , heart, and blood vessels) tissues
KERENDIA English Product Monograph - Bayer Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR) Finerenone binds to the MR and blocks the binding of aldosterone, a component of the renin-angiotensin-aldosterone-system (RAAS)
DailyMed - KERENDIA- finerenone tablet, film coated 12 1 Mechanism of Action - Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR), which is activated by aldosterone and cortisol and regulates gene
Kerendia (Bayer Healthcare Pharmaceuticals Inc. ): FDA Package Insert Bayer Healthcare Pharmaceuticals Inc : Kerendia is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS The use of finerenone in patients with moderate hepatic impairment may require additional monitoring due to an increase in finerenone exposure Additional serum potassium monitoring and adaptation of monitoring have to be considered according to patient characteristics (see sections 4 2 and 5 2)
Kerendia, INN-finerenone - medicines Kerendia contains the active substance finerenone Finerenone works by blocking the action of certain hormones (mineralocorticoids) that can damage your kidneys and heart Kerendia is used for the treatment of adults with chronic kidney disease (stage 3 and 4 with abnormal presence of the protein albumin in the urine) associated with type 2
Kerendia Prescribing Information Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR), which is activated by aldosterone and cortisol and regulates gene transcription Finerenone blocks MR mediated sodium reabsorption and MR overactivation in both epithelial (e g , kidney) and nonepithelial (e g , heart, and blood vessels) tissues
Finerenone (KERENDIA) National Drug Monograph April 2022 Description Mechanism of Action • Finerenone is a nonsteroidal, selective mineralocorticoid receptor antagonist (MRA) that blocks sodium reabsorption, and mineralocorticoid receptor overactivation in the kidney as well as the heart and blood vessels Per the product information, mineralocorticoid receptor overactivation is thought to contribute to fibrosis and inflammation Finerenone has a